Australia's most trusted
source of pharma news
Posted 17 February 2026 AM
An 'unprecedented' lightning-quick Federal Court ruling has seen AstraZeneca granted an injunction to protect its most important market in Australia worth $130 million-plus a year.
Justice Kylie Downes granted the interlocutory injunction just six working days after the interlocutory hearing on 6 February, and two months after AstraZeneca began legal proceedings. The injunction prevents Pharmacor from launching a generic version of Forxiga, which it had planned to do on 1 April. It also covers combination products which include the same active ingredient, Xigduo, Qtern, and Sidapvia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.